LEADER 01479nam  2200409Ia 450 
001 9910698987503321
005 20090615143102.0
035   $a(CKB)5470000002397997
035   $a(OCoLC)399838071
035   $a(EXLCZ)995470000002397997
100   $a20090615d2006      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for industry$b[electronic resource] $eQ3B(R2) impurities in new drug products
210  1$aRockville, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research,$d[2006]
215   $a8 pages $cdigital, PDF file
300   $aTitle from PDF title page (viewed on June 15, 2009).
300   $a"ICH".
300   $a"July 2006" .
300   $a"Revision 2".
517   $aGuidance for industry 
606   $aDrug development$xGovernment policy$zUnited States
606   $aDrug adulteration$xGovernment policy$zUnited States
615  0$aDrug development$xGovernment policy
615  0$aDrug adulteration$xGovernment policy
712 02$aCenter for Drug Evaluation and Research (U.S.)
712 02$aCenter for Biologics Evaluation and Research (U.S.)
712 12$aInternational Conference on Harmonisation.
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910698987503321
996   $aGuidance for industry$93434577
997   $aUNINA